Interleukin-2 (IL-2) is an important member of the cytokines that play critical roles in carcinogenesis. Many studies have investigated the association between IL-2 rs2069762 polymorphism and cancer risk; however, the results remain controversial. The aim of this study is to assess the correlation between IL-2 rs2069762 polymorphism and cancer risk. All eligible case-control studies accorded with criteria published up to March 30, 2015 were identified by searching Embase and PubMed databases. Association between IL-2 rs2069762 polymorphism and cancer risk was assessed by crude odds ratios (ORs) with 95% confidence intervals (CIs), respectively. Ten case-control studies from nine publications with 3095 cases and 4480 controls were included. Overall, IL-2 rs2069762 polymorphism was not associated with cancer risk in five genetic models (G vs. T: OR = 1.07, 95% CI = 0.95-1.21, P = 0.278; GG vs. TT: OR = 1.16, 95% CI = 0.86-1.57, P = 0.317; GG + TG vs. TT: OR = 1.09, 95% CI = 0.93-1.28, P = 0.273; GG vs. TT + TG: OR = 1.11, 95% CI = 0.85-1.44, P = 0.451; TG vs. TT: OR = 1.08, 95% CI = 0.92-1.28, P = 0.339, respectively). Similar results were also obtained after stratified by ethnicity and cancer type. This meta-analysis indicates that IL-2 rs2069762 T>G polymorphism is not associated with cancer risk. And the same conclusion is drawn after stratified by cancer type and ethnicity.